Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Gender as risk factor for autoimmune diseases.
Primary progressive multiple sclerosis-why we are failing.
USPTO list of patent term extensions
Viral triggers of multiple sclerosis.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Remyelination in experimental models of toxin-induced demyelination.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.
Biogen Idec and Genentech announce restructuring of anti-CD20 collaboration agreement
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.
Pages
« first
‹ previous
…
12
13
14
15
16
17
18
19
20
…
next ›
last »